EGFR and non-small cell lung carcinoma: Unfortunately, the ability of these EGFR inhibitors to successfully treat NSCLC is short-lived in subsequent therapies due to acquired T790M missense secondary mutations in EGFR, contributing to drug resistance in around 50% of patients.